Lilly CEO: Find overlap between corporate mission, philanthropy
John Lechleiter told local leaders Friday morning that while community engagement might not immediately impact the bottom line, it can be beneficial to a company’s ongoing mission.
John Lechleiter told local leaders Friday morning that while community engagement might not immediately impact the bottom line, it can be beneficial to a company’s ongoing mission.
Dave Ricks will begin guiding the company during a period of relative calm compared with the trying times John Lechleiter navigated during his eight years at the helm.
David Ricks fit the bill for the top job at Eli Lilly and Co. after 20 years with the firm in product development, sales and marketing, and public policy, according to outgoing CEO John Lechleiter.
John Lechleiter has been the company’s CEO since 2008. The announcement Wednesday morning of his retirement comes one day after the firm announced strong revenue and profit for its second quarter, indicating that Lechleiter’s initiatives have paid off.
John Lechleiter, CEO of Eli Lilly and Co., said the company remained confident about its drug pipeline even after it weathered a string of failed clinical trials.
United Way Worldwide President and CEO Brian Gallagher said John Lechleiter will help strengthen the not-for-profit network's capacity to meet growing human needs around the world.
Lilly CEO John Lechleiter was paid $11.2 million in salary, bonus, stock and perks last year, according to Lilly’s proxy statement filed Monday morning. That represented a 10-percent increase over his take in 2012.
John Lechleiter, Angela Braly and two other local business leaders have pledged a combined $3 million to United Way of Central Indiana over the next four years. United Way is trying to raise $42.5 million by the end of the year.
Eli Lilly and Co. Chairman and CEO John Lechleiter is back to full-time work after taking a leave in May to have surgery for a dilated aorta, the company announced Monday morning.
Eli Lilly and Co. CEO John Lechleiter underwent a scheduled surgery Monday for a heart defect, and the repair to the aorta is functioning as intended, the Indianapolis-based drugmaker said.
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. CEO John Lechleiter plans to tell a technology conference Thursday.
Eli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly will be just fine after it has sustained the damage of the next three years.
Cymbalta racked up $3.5 billion in sales last year, and some analysts say it may approach $5 billion before generic competition arrives in 2013.
Eli Lilly and Co. CEO John Lechleiter’s total compensation increased $4.1 million in 2009.
Since John Lechleiter was named CEO 18 months ago, he’s bet that Eli Lilly and Co. could face down its looming patent challenges
by launching innovative new medicines. Today’s announcement of 5,500 job cuts by the end of 2011 and a restructuring of the
company’s business units ups the ante on that bet, while indicating that it isn’t working yet.
After so many years of trying to tap every possible cubicle-dweller for donations, United Way of Central Indiana is putting
more effort into the richest veins in the workplace—the folks in corner offices.
Eli Lilly and Co. CEO John Lechleiter and his wife, Sarah, have pledged to give the United Way of Central Indiana a total
of $1 million over the next four years as a “challenge to CEOs and other community leaders to step up their giving.”
Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year,
Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
John C. Lechleiter, whom Eli Lilly and Co.’s board voted to replace Sidney Taurel as CEO, is known for getting things done
and yet also for being good at analysis and relating to people under him. Taurel will step down at the end of March but remain
chairman until the end of 2008.